Form 4: List Alan reports acquisition/exercise transactions in HURA

Q: What are the key terms of Alan List’s new stock options from TuHURA (HURA)?

The new grant covers 156,240 options with a $1.29 exercise price per share. These options expire on February 12, 2036 and were issued under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan as an annual director award.

Q: How do Alan List’s TuHURA (HURA) options vest over time?

The newly granted 156,240 options vest in three equal installments. One-third becomes exercisable on each of the first, second, and third anniversaries of February 12, 2026 , aligning the director’s compensation with multi‑year service to the company.

Q: What prior stock options for TuHURA (HURA) does Alan List hold?

Alan List also holds a prior annual option grant of 51,275 options with a $4.11 exercise price. These options were granted on January 2, 2025 and expire on January 2, 2035 , with similar three‑year vesting based on annual anniversaries.

Q: Is Alan List’s Form 4 for TuHURA (HURA) a purchase or a compensation grant?

The Form 4 reflects a compensation grant , not an open‑market share purchase. The transaction code indicates a grant or award of 156,240 stock options under TuHURA’s 2024 Equity Incentive Plan as part of his role as a director.

Q: What role does Alan List hold at TuHURA Biosciences (HURA)?

Alan List is reported as a director of TuHURA Biosciences, Inc. His Form 4 filing details stock option awards tied to his director service, including a new grant of 156,240 options and a previously granted 51,275-option award.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

List Alan reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider List Alan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	156,240	$0.00	$0.00
holding	Options (Right to Buy)	--	--	--

Holdings After Transaction: Options (Right to Buy) — 207,515 shares (Direct)

Footnotes (2)

F1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
F2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/17/2026 - 04:16 PM

FAQ

What did TuHURA Biosciences (HURA) director Alan List report on this Form 4?

Alan List reported receiving an annual stock option grant. He was awarded 156,240 options to buy TuHURA common stock at $1.29 per share, expiring in 2036, as equity-based compensation under the company’s 2024 Equity Incentive Plan.

What are the key terms of Alan List’s new stock options from TuHURA (HURA)?

The new grant covers 156,240 options with a $1.29 exercise price per share. These options expire on February 12, 2036 and were issued under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan as an annual director award.

How do Alan List’s TuHURA (HURA) options vest over time?

The newly granted 156,240 options vest in three equal installments. One-third becomes exercisable on each of the first, second, and third anniversaries of February 12, 2026, aligning the director’s compensation with multi‑year service to the company.

What prior stock options for TuHURA (HURA) does Alan List hold?

Alan List also holds a prior annual option grant of 51,275 options with a $4.11 exercise price. These options were granted on January 2, 2025 and expire on January 2, 2035, with similar three‑year vesting based on annual anniversaries.

Is Alan List’s Form 4 for TuHURA (HURA) a purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open‑market share purchase. The transaction code indicates a grant or award of 156,240 stock options under TuHURA’s 2024 Equity Incentive Plan as part of his role as a director.

What role does Alan List hold at TuHURA Biosciences (HURA)?

Alan List is reported as a director of TuHURA Biosciences, Inc. His Form 4 filing details stock option awards tied to his director service, including a new grant of 156,240 options and a previously granted 51,275-option award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

List Alan

(Last)

(First)

(Middle)

10500 UNIVERSITY CENTER DRIVE, SUITE 110

(Street)

TAMPA

33612

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options (Right to Buy)	$1.29	02/12/2026⁽¹⁾		A		156,240		⁽¹⁾	02/12/2036	Common Stock	156,240	$0	156,240	D
Options (Right to Buy)	$4.11							⁽²⁾	01/02/2035	Common Stock	51,275		51,275	D

Explanation of Responses:

1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

	/s/ Dan Dearborn as Power of Attorney for Alan List	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR